Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2021 · 10-Q
Revenue$239.00K$239.00K−58.1% vs Q1 2020 Net Income-$4.12M-$4.12MN/M vs Q1 2020 EPS Diluted$0.00$0.00— vs Q1 2020 Operating Income-$19,570,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Margins · derivedOperating margin-8188.3%−6831.6 pt vs Q1 2020
Net margin-1725.1%
ended Mar 31, 2021 · filed May 17, 2021 · 47 d after period end